Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biliary neuroendocrine tumors: a narrative review of current diagnostics and management strategies.

Chinese clinical oncology·2026
Same author

ASO Author Reflections: The Need for Improved Documentation at Multidisciplinary Tumor Boards.

Annals of surgical oncology·2026
Same author

Molecular Characterization of Small Extracellular Vesicles in Pancreatic Cancer Patients Treated with Neoadjuvant Chemotherapy Followed by Stereotactic Body Radiation.

Cancers·2026
Same author

ASO Visual Abstract: Multidisciplinary Tumor Board Documentation-Assessing its Frequency, Quality, and Impact.

Annals of surgical oncology·2026
Same author

Niraparib in pancreatic cancer with germline or somatic DNA damage repair (DDR) gene alterations (BRCA and beyond): A phase II study (NIRA-PANC).

The oncologist·2026
Same author

Multidisciplinary Tumor Board Documentation: Assessing its Frequency, Quality, and Impact.

Annals of surgical oncology·2026

Related Experiment Video

Updated: May 10, 2025

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

673

Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights.

Ashish Manne1, Yonghua Bao2, Ankur Sheel1

  • 1Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center (OSUCCC), Columbus, OH, United States.

Frontiers in Oncology
|April 22, 2025
PubMed
Summary
This summary is machine-generated.

Serum MUC5AC (sMUC5AC) levels show promise as a prognostic biomarker for pancreatic ductal adenocarcinoma (PDA) patients. Higher sMUC5AC is linked to poorer outcomes, aiding in post-surgery risk stratification.

Keywords:
FOLFIRINOXMUC5ACbiomarkerneoadjuvant therapypancreatic cancerpredictingprognostic markerserum MUC5AC

More Related Videos

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma
05:44

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma

Published on: November 5, 2020

3.3K
Management of the Uncinate Process in No-Touch Laparoscopic Pancreaticoduodenectomy
09:32

Management of the Uncinate Process in No-Touch Laparoscopic Pancreaticoduodenectomy

Published on: May 5, 2023

746

Related Experiment Videos

Last Updated: May 10, 2025

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

673
Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma
05:44

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma

Published on: November 5, 2020

3.3K
Management of the Uncinate Process in No-Touch Laparoscopic Pancreaticoduodenectomy
09:32

Management of the Uncinate Process in No-Touch Laparoscopic Pancreaticoduodenectomy

Published on: May 5, 2023

746

Area of Science:

  • Oncology
  • Biomarker Discovery
  • Gastroenterology

Background:

  • Investigating serum MUC5AC (sMUC5AC) in pancreatic ductal adenocarcinoma (PDA).
  • Assessing sMUC5AC in patients undergoing neoadjuvant therapy (NAT) and upfront surgery (UpS).

Purpose of the Study:

  • To determine the association between sMUC5AC levels and patient outcomes in resected PDA.
  • To evaluate sMUC5AC as a prognostic biomarker for PDA patients.

Main Methods:

  • Enzyme-linked immunoassays (ELISA) used to measure sMUC5AC levels in serum samples.
  • Statistical analyses included logistic regression, Cox regression, ANOVA, t-tests, and Wilcoxon tests.
  • Exploration of sMUC5AC combined with Carbohydrate antigen (CA) 19-9 for recurrence prediction.

Main Results:

  • Elevated sMUC5AC associated with adverse pathological outcomes in NAT cohort.
  • Higher sMUC5AC independently predicted shorter progression-free survival (PFS) and overall survival (OS) in R0/R1 resections.
  • Combined sMUC5AC and CA 19-9 improved recurrence prediction sensitivity and specificity.
  • Higher sMUC5AC linked to earlier recurrence and poorer survival outcomes post-surgery.

Conclusions:

  • sMUC5AC demonstrates significant clinical utility as a prognostic biomarker in resected PDA.
  • Further large-scale studies are required to validate findings and establish clinical thresholds for sMUC5AC.
  • sMUC5AC aids in risk stratification for PDA patients post-resection.